Targeting synovial neoangiogenesis in rheumatoid arthritis

Autoimmunity Reviews

Volumn 16, Issue 6, 2017, Pages 594-601

  Leblond, Agathe ^a   Allanore, Yannick ^a   Avouac, Jérôme ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Endothelial cells; Rheumatoid arthritis; Synovial angiogenesis; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CAPILLARY DENSITY; HUMAN; HYPOXEMIA; HYPOXIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; ANIMAL; ARTHRITIS, RHEUMATOID; BLOOD VESSEL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ANIMALS; ARTHRITIS, RHEUMATOID; BLOOD VESSELS; HUMANS; HYPOXIA; NEOVASCULARIZATION, PATHOLOGIC; SYNOVIAL MEMBRANE;

EID: 85018258382     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.04.005     Document Type: Review

References (90)

1. Criscione, L.G., E.W., SC. Tumor necrosis factor-alpha for the treatment of rheumatic diseases. Curr Opin Rheumatol 14 (2002), 204–211.
2. Firestein, G.S., Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103 (1999), 3–4.
3. FitzGerald, O., Soden, M., Yanni, G., Robinson, R., Bresnihan, B., Morphometric analysis of blood vessels in synovial membranes obtained from clinical affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 50 (1991), 792–796.
4. Stevens, C.R., Blake, D.R., Merry, P., Revell, P.A., Levick, J.R., A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 34 (1991), 1508–1513.
5. Paleolog, E.M., Angiogenesis in rheumatoid arthritis. Arthritis Res, 4, 2002.
6. Rooney, M., Condell, D., Quinlan, W., Daly, L., Whelan, A., Feighery, C., et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31 (1988), 956–963.
7. Bodamyali, T., Stevens, C.R., Billingham, M.E., Ohta, S., Blake, D.R., Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis 57 (1998), 703–710.
8. Marrelli, A., Cipriani, P., Liakouli, V., Carubbi, F., Perricone, C., Perricone, R., et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?. Autoimmun Rev 10 (2011), 595–598.
9. del Rey, M.J., Izquierdo, E., Caja, S., Usategui, A., Santiago, B., Galindo, M., et al. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum 60 (2009), 2926–2934.
10. Del Rey, M.J., Izquierdo, E., Usategui, A., Gonzalo, E., Blanco, F.J., Acquadro, F., et al. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 62 (2010), 3584–3594.
11. Maracle, C.X., Tas, S.W., Inhibitors of angiogenesis: ready for prime time?. Best Pract Res Clin Rheumatol 28 (2014), 637–649.
12. Izquierdo, E., Canete, J.D., Celis, R., Santiago, B., Usategui, A., Sanmarti, R., et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One, 4, 2009, e8131.
13. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997), 964–967.
14. Avouac, J., Wipff, J., Goldman, O., Ruiz, B., Couraud, P.O., Chiocchia, G., et al. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 58 (2008), 3550–3561.
15. Ruger, B., Giurea, A., Wanivenhaus, A.H., Zehetgruber, H., Hollemann, D., Yanagida, G., et al. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 50 (2004), 2157–2166.
16. Hirohata, S., Yanagida, T., Nampei, A., Kunugiza, Y., Hashimoto, H., Tomita, T., et al. Enhanced generation of endothelial cells from CD34 + cells of the bone marrow in rheumatoid arthritis: possible role in synovial neovascularization. Arthritis Rheum 50 (2004), 3888–3896.
17. Grisar, J., Aletaha, D., Steiner, C.W., Kapral, T., Steiner, S., Seidinger, D., et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111 (2005), 204–211.
18. Herbrig, K., Haensel, S., Oelschlaegel, U., Pistrosch, F., Foerster, S., Passauer, J., Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 65 (2006), 157–163.
19. Allanore, Y., Batteux, F., Avouac, J., Assous, N., Weill, B., Kahan, A., Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25 (2007), 60–66.
20. Egan, C.G., Caporali, F., Garcia-Gonzalez, E., Galeazzi, M., Sorrentino, V., Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics. Rheumatology (Oxford) 47 (2008), 1484–1488.
21. Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y., Ikeda, Y., Defective vasculogenesis in systemic sclerosis. Lancet 364 (2004), 603–610.
22. Jodon de Villeroche, V., Avouac, J., Ponceau, A., Ruiz, B., Kahan, A., Boileau, C., et al. Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. Arthritis Res Ther, 12, 2010 [R27].
23. Tas, S.W., Maracle, C.X., Balogh, E., Szekanecz, Z., Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol 12 (2016), 111–122.
24. Akhavani, M.A., Madden, L., Buysschaert, I., Sivakumar, B., Kang, N., Paleolog, E.M., Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther, 11, 2009, R64.
25. Gaber, T., Dziurla, R., Tripmacher, R., Burmester, G.R., Buttgereit, F., Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!. Ann Rheum Dis 64 (2005), 971–980.
26. Peters, C.L., Morris, C.J., Mapp, P.I., Blake, D.R., Lewis, C.E., Winrow, V.R., The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 50 (2004), 291–296.
27. Brouwer, E., Gouw, A.S.H., Posthumus, M.D., van Leeuwen, M.A., Boerboom, A.L., Bijzet, J., et al. Hypoxia inducible factor-1-alpha is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 27 (2009), 945–951.
28. Khanum, S.A., Shashikanth, S., Deepak, A.V., Synthesis and anti-inflammatory activity of benzophenone analogues. Bioorg Chem 32 (2004), 211–222.
29. Prabhakar, B.T., Khanum, S.A., Shashikanth, S., Salimath, B.P., Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo. Invest New Drugs 24 (2006), 471–478.
30. Shankar, J., Thippegowda, P.B., Kanum, S.A., Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats. Biochem Biophys Res Commun 387 (2009), 223–228.
31. Park, S.Y., Lee, S.W., Kim, H.Y., Lee, W.S., Hong, K.W., Kim, C.D., HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1alpha activation. Eur J Immunol 45 (2015), 1216–1227.
32. Ballara, S., Taylor, P.C., Reusch, P., Marmé, D., Feldmann, M., Maini, R.N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44 (2001), 2055–2064.
33. Scola, M.P., Imagawa, T., Boivin, G.P., Giannini, E.H., Glass, D.N., Hirsch, R., et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 44 (2001), 794–801.
34. Berse, B., Hunt, R.J., Diegel, P., Morganelli, K.-T., Yeo, F., Fava, B.R.A., Hypoxia augments cytokine (transforming growth factor-beta (TGF-B) and IL-1)- induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 115 (1991), 176–182.
35. Cho, C.S., Cho, M.L., Min, S.Y., Kim, W.U., Min, D.J., Lee, S.S., et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 164 (2000), 5055–5061.
36. Paleolog, E.M., Young, S., Stark, A.C., McCloskey, R.V., Feldmann, M., Maini, R.N., Modulation of angiogenic vascular endothelial growrh factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41 (1998), 1258–1265.
37. Macias, I., Garcia-Perez, S., Ruiz-Tudela, M., Medina, F., Chozas, N., Giron-Gonzales, J., Modification of pro-and anti inflammatory cytokines and vascular-related molecules by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. J Rheumatol 32 (2005), 2102–2108.
38. Shahrara, S., Volin, M.V., Connors, M.A., Haine, G.K., Koch, A.E., Differential expression of the angiogenic tie receptor family in arthritic and normal synovial tissue. Arthritis Res 4 (2002), 201–208.
39. DeBusk, L.M., Chen, Y., Nishishita, T., Chen, J., Thomas, J.W., Lin, P.C., Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 48 (2003), 2461–2471.
40. Scott, B.B., Zaratin, P.F., Gilmartin, A.G., Hansbury, M.J., Colombo, A., Belpasso, C., et al. TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway. Biochem Biophys Res Commun 328 (2005), 409–414.
41. Chen, Y., Donnelly, E., Kobayashi, H., Debusk, L.M., Lin, P.C., Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52 (2005), 1585–1594.
42. Kanakaraj, P., Puffer, B.A., Yao, X.T., Kankanala, S., Boyd, E., Shah, R.R., et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 4 (2012), 600–613.
43. Leibovich, S.J., Polverini, P.J., Shepard, H.M., Wiseman, D.M., Shively, V., Nuseir, N., Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329 (1987), 630–632.
44. Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17 (1997), 4015–4023.
45. Fisher, B., Donatien, P., Filer, A., Winlove, C., McInnes, I., Buckley, C.D., et al. Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. Clin Exp Rheumatol 34 (2016), 1072–1076.
46. Taylor, P., Patel, S., Paleolog, E., McCloskey, R.V., Feldmann, M., Maini, R.N., Reduced synovial vascularity following TNF alpha blockade in rheumatoid arthritis. Arthritis Rheum, 41, 1998.
47. Stamp, L.K., James, M.J., Cleland, L.G., Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis ?. Immunol Cell Biol 82 (2004), 1–9.
48. Shahrara, S., Huang, Q., Mardelin, A.M.I., Pope, R.M., TH-17 cells in rheumatoid arthritis. Arthritis Res Ther, 10, 2008.
49. Pickens, S.R., Volin, M.V., Mandelin, A.M. 2nd, Kolls, J.K., Pope, R.M., Shahrara, S., IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184 (2010), 3233–3241.
50. Buckley, C.D., Amft, N., Bradfield, P.F., Pilling, D., Ross, E., Arenzana-Seisdedos, F., et al. Persistent induction of the chemokine receptor CXCR4 by TGF- 1 on synovial T cells contributes to their accumulation within the rheumatoid Synovium. J Immunol 165 (2000), 3423–3429.
51. Nanki, T., Hayashida, K., El-Gabalawy, H.S., Suson, S., Shi, K., Girschick, H.J., et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 + T cell accumulation in rheumatoid arthritis Synovium. J Immunol 165 (2000), 6590–6598.
52. Matthys, P., Hatse, S., Vermeire, K., Wuyts, A., Bridger, G., Henson, G.W., et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN- receptor-deficient mice. J Immunol 167 (2001), 4686–4692.
53. Watanabe, K., Penfold, M.E., Matsuda, A., Ohyanagi, N., Kaneko, K., Miyabe, Y., et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum 62 (2010), 3211–3220.
54. Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., et al. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res 19 (2013), 4433–4445.
55. Ruth, J.H., Haas, C.S., Park, C.C., Amin, M.A., Martinez, R.J., Haines, G.K. III, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 54 (2006), 765–778.
56. Nanki, T., Shimaoka, T., Hayashida, K., Taniguchi, K., Yonehara, S., Miyasaka, N., Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum 52 (2005), 3004–3014.
57. Isozaki, T., Arbab, A.S., Haas, C.S., Amin, M.A., Arendt, M.D., Koch, A.E., et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 65 (2013), 1736–1746.
58. Hirata, S., Mastubara, T., Saura, R., Tateishi, H., Hirohata, K., Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32 (1989), 1065–1073.
59. Nagashima, M., Yoshino, S., Aono, H., Takai, M., Sasano, M., Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 116 (1999), 360–365.
60. Fiehn, C., Wunder, A., Krienke, S., Max, R., Ho, A.D., Moehler, T., Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int 25 (2005), 108–113.
61. Ballara, S., Taylor, P.C., Reusch, P., Marme, D., Feldmann, M., Maini, R.N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44 (2001), 2055–2064.
62. Umemura, M., Isozaki, T., Ishii, S., Seki, S., Oguro, N., Miura, Y., et al. Reduction of serum ADAM17 level accompanied with decreased cytokines after Abatacept therapy in patients with rheumatoid arthritis. Int J Biomed Sci 10 (2014), 229–235.
63. Hirohata, S., Abe, A., Murasawa, A., Kanamono, T., Tomita, T., Yoshikawa, H., Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis. Mod Rheumatol, 2016, 1–22.
64. De Bandt, M., Ben Mahdi, M.H., Ollivier, V., Grossin, M., Dupuis, M., Gaudry, M., et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 171 (2003), 4853–4859.
65. Yoo, S.A., Yoon, H.J., Kim, H.S., Chae, C.B., De Falco, S., Cho, C.S., et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 60 (2009), 345–354.
66. Wang, Y., Da, G., Li, H., Zheng, Y., Avastin exhibits therapeutic effects on collagen-induced arthritis in rat model. Inflammation 36 (2013), 1460–1467.
67. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994), 315–328.
68. Holmgren, L., O'Reilly, M.S., Folkman, J., Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1 (1995), 149–153.
69. Kato, K., Miyake, K., Igarashi, T., Yoshino, S., Shimada, T., Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int 25 (2005), 522–529.
70. Antoine, N., Greimers, R., De Roanne, C., Kusaka, M., Heinen, E., Simar, L.J., et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54 (1994), 2073–2076.
71. Maniwa, Y., Okada, M., Ishii, N., Kiyooka, K., Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 114 (1998), 1668–1675.
72. Shishido, T., Yashoshima, T., Denno, R., Mukaiya, M., Sato, N., Hirata, K., Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cysplatin. J Cancer Res 89 (1998), 963–969.
73. De Bandt, M., Grossin, M., Weber, A.-J., Chopin, M., Elbim, C., Pla, M., et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-170 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 43 (2000), 2056–2063.
74. Lu, Q., Tong, B., Luo, Y., Sha, L., Chou, G., Wang, Z., et al. Norisoboldine suppresses VEGF-induced endothelial cell migration via the cAMP-PKA-NF-kappaB/Notch1 pathway. PLoS One, 8, 2013, e81220.
75. Yue, L., Shen, Y.X., Feng, L.J., Chen, F.H., Yao, H.W., Liu, L.H., et al. Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 567 (2007), 166–170.
76. Chen, N., Gao, R.F., Yuan, F.L., Zhao, M.D., Recombinant human Endostatin suppresses mouse osteoclast formation by inhibiting the NF-kappaB and MAPKs signaling pathways. Front Pharmacol, 7, 2016, 145.
77. Su, C.M., Hsu, C.J., Tsai, C.H., Huang, C.Y., Wang, S.W., Tang, C.H., Resistin promotes angiogenesis in endothelial progenitor cells through inhibition of MicroRNA206: potential implications for rheumatoid arthritis. Stem Cells 33 (2015), 2243–2255.
78. Dickson, P.V., Hamner, J.B., Sims, T.L., Fraga, C.H., Ng, C.Y., Rajasekeran, S., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007), 3942–3950.
79. Turley, R.S., Fontanella, A.N., Padussis, J.C., Toshimitsu, H., Tokuhisa, Y., Cho, E.H., et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res 18 (2012), 3328–3339.
80. Vredenburgh, J.J., Desjardins, A., Herndon, J.E. 2nd, Dowell, J.M., Reardon, D.A., Quinn, J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007), 1253–1259.
81. Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25 (2007), 1539–1544.
82. Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008), 2013–2019.
83. Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009), 1227–1234.
84. Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A., et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study. J Clin Oncol 28:19 (2010), 3191–3198.
85. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. Bevacizumab plus Irinotecan, fluorouracil, and Leucovorin for metastatic colorectal cancer. New Engl J Med 350 (2004), 2335–2343.
86. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., et al. Paclitaxel-carboplatin alone or with Bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
87. Tewari, K.S., Sill, M.W., Long, H.J. III, Penson, R.T., Huang, H., Ramondetta, L.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 (2014), 734–743.
88. Yonekawa, Y., Kim, I.K., Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med, 5, 2014, a017178.
89. Agarwal, A., Afridi, R., Hassan, M., Sadiq, M.A., Sepah, Y.J., Do, D.V., et al. Novel therapies in development for diabetic macular edema. Curr Diab Rep, 15, 2015, 75.
90. Yadav, L., Puri, N., Rastogi, V., Satpute, P., Sharma, V., Tumour angiogenesis and Angiogenic inhibitors: a review. J Clin Diagn Res 9 (2015), XE01–XXE5.